公开(公告)号：US06875757B2

公开(公告)日：2005-04-05

申请号：US09811838

申请日：2001-03-19

申请人： Duane D. Miller ,  Gabor Tigyi ,  James T. Dalton ,  Vineet M. Sardar ,  Don B. Elrod ,  Huiping Xu ,  Daniel L. Baker ,  Dean Wang ,  Karoly Liliom ,  David J. Fischer ,  Tamas Virag ,  Nora Nusser

发明人： Duane D. Miller ,  Gabor Tigyi ,  James T. Dalton ,  Vineet M. Sardar ,  Don B. Elrod ,  Huiping Xu ,  Daniel L. Baker ,  Dean Wang ,  Karoly Liliom ,  David J. Fischer ,  Tamas Virag ,  Nora Nusser

IPC分类号： C12N15/09 ,  A61K31/27 ,  A61K31/66 ,  A61K31/685 ,  A61P17/02 ,  A61P35/00 ,  A61P43/00 ,  C07F9/09 ,  C07F9/10 ,  C07F9/11 ,  C07F9/17 ,  C07F9/22 ,  C07F9/38 ,  C07F9/40 ,  A61K31/661 ,  C07F9/06

CPC分类号： C07F9/4028 ,  A61K31/27 ,  A61K31/66 ,  C07F9/091 ,  C07F9/093 ,  C07F9/094 ,  C07F9/098 ,  C07F9/11 ,  C07F9/17 ,  C07F9/222 ,  C07F9/3808

摘要： The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.

公开(公告)号：US20050261252A1

公开(公告)日：2005-11-24

申请号：US11067884

申请日：2005-02-28

申请人： Duane Miller ,  Gabor Tigyi ,  James Dalton ,  Vineet Sardar ,  Don Elrod ,  Huiping Xu ,  Daniel Baker ,  Dean Wang ,  Karoly Liliom ,  David Fischer ,  Tamas Virag ,  Nora Nusser

发明人： Duane Miller ,  Gabor Tigyi ,  James Dalton ,  Vineet Sardar ,  Don Elrod ,  Huiping Xu ,  Daniel Baker ,  Dean Wang ,  Karoly Liliom ,  David Fischer ,  Tamas Virag ,  Nora Nusser

IPC分类号： C12N15/09 ,  A61K31/27 ,  A61K31/66 ,  A61K31/685 ,  A61P17/02 ,  A61P35/00 ,  A61P43/00 ,  C07F9/09 ,  C07F9/10 ,  C07F9/11 ,  C07F9/17 ,  C07F9/22 ,  C07F9/38 ,  C07F9/40 ,  A61K31/675 ,  A61K31/663 ,  C07F9/28

摘要： The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.

摘要翻译： 本发明涉及本文公开的式（I）化合物以及包括那些化合物的药物组合物。 还公开了使用这些化合物的方法，其具有活性作为LPA受体的激动剂或拮抗剂; 这些方法包括抑制LPA受体的LPA活性，调节LPA受体活性，治疗癌症，增强细胞增殖和治疗伤口。

公开(公告)号：US20050085449A1

公开(公告)日：2005-04-21

申请号：US10684582

申请日：2003-10-15

申请人： James Dalton ,  Duane Miller ,  Huiping Xu ,  Vipin Nair

发明人： James Dalton ,  Duane Miller ,  Huiping Xu ,  Vipin Nair

IPC分类号： A61K31/165 ,  A61K31/21 ,  A61K31/277 ,  A61K31/655 ,  A61K31/66 ,  C07C235/24 ,  C07C255/60 ,  C07D207/44 ,  C07D207/452

CPC分类号： C07D207/452 ,  A61K31/165 ,  A61K31/21 ,  A61K31/277 ,  A61K31/655 ,  A61K31/66 ,  C07C235/24 ,  C07C255/60

摘要： The present invention relates to a novel class of anti-cancer compounds, which contain a haloacetamide or azide moiety and are, in one embodiment, alkylating agents. These agents, either alone or in a composition, are useful for treating cancer, preventing cancer, delaying the progression of cancer, treating and/or preventing the recurrence of cancer, suppressing, inhibiting or reducing the incidence of cancer, or inducing apoptosis in a cancer cell. Accordingly, the present invention provides a) methods of treating cancer in a subject; b) methods of preventing cancer in a subject; c) methods of delaying the progression of cancer in a subject; d) methods of treating the recurrence of cancer in a subject; e) methods of preventing the recurrence of cancer in a subject; f) methods of suppressing, inhibiting or reducing the incidence of cancer in a subject; and g) methods of inducing apoptosis in a cancer cell; by administering to the subject an anti-cancer compound of the present invention or an analog or metabolite thereof, its N-oxide, ester, pharmaceutically acceptable salt, hydrate, or any combination thereof as described herein.

公开(公告)号：US20050137172A1

公开(公告)日：2005-06-23

申请号：US10963761

申请日：2004-10-14

申请人： James Dalton ,  Duane Miller ,  Vipin Nair ,  Huiping Xu

发明人： James Dalton ,  Duane Miller ,  Vipin Nair ,  Huiping Xu

IPC分类号： A61K31/165 ,  A61K31/21 ,  A61K31/277 ,  A61K31/655 ,  A61K31/66 ,  C07C235/24 ,  C07C255/60 ,  C07D207/44 ,  C07D207/452 ,  A61K31/195 ,  A61K31/32 ,  A61K31/4015

CPC分类号： C07D207/452 ,  C07C235/24 ,  C07C255/60

摘要： The present invention relates to a novel class of anti-cancer compounds, which contain a haloacetamide or azide moiety and are, in one embodiment, alkylating agents. These agents, either alone or in a composition, are useful for treating cancer, preventing cancer, delaying the progression of cancer, treating and/or preventing the recurrence of cancer, suppressing, inhibiting or reducing the incidence of cancer, or inducing apoptosis in a cancer cell. Accordingly, the present invention provides a) methods of treating cancer in a subject; b) methods of preventing cancer in a subject; c) methods of delaying the progression of cancer in a subject; d) methods of treating the recurrence of cancer in a subject; e) methods of preventing the recurrence of cancer in a subject; f) methods of suppressing, inhibiting or reducing the incidence of cancer in a subject; and g) methods of inducing apoptosis in a cancer cell; by administering to the subject an anti-cancer compound of the present invention or an analog or metabolite thereof, its N-oxide, ester, pharmaceutically acceptable salt, hydrate, or any combination thereof as described herein.

摘要翻译： 本发明涉及一类新的抗癌化合物，其含有卤代乙酰胺或叠氮化物部分，在一个实施方案中是烷化剂。 这些药物单独或组合物可用于治疗癌症，预防癌症，延缓癌症进展，治疗和/或预防癌症复发，抑制，抑制或降低癌症发生率或诱导癌细胞凋亡 癌细胞。 因此，本发明提供了a）在受试者中治疗癌症的方法; b）预防受试者癌症的方法; c）延缓受试者癌症进展的方法; d）治疗患者癌症复发的方法; e）预防受试者癌症复发的方法; f）抑制或抑制受试者癌症发病率的方法; 和g）诱导癌细胞凋亡的方法; 通过向受试者施用本文所述的抗癌化合物或其类似物或代谢物，其N-氧化物，酯，药学上可接受的盐，水合物或其任何组合。